HUTCHMED (China) Limited (LON:HCM - Get Free Report)'s stock price passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 289.99 ($3.65) and traded as low as GBX 261 ($3.29). HUTCHMED shares last traded at GBX 264 ($3.33), with a volume of 39,973 shares traded.
HUTCHMED Stock Performance
The company has a quick ratio of 2.97, a current ratio of 2.81 and a debt-to-equity ratio of 11.78. The stock has a market cap of £2.26 billion, a P/E ratio of -6,600.00 and a beta of 0.76. The firm's 50-day moving average is GBX 284.76 and its two-hundred day moving average is GBX 289.81.
About HUTCHMED
(
Get Free Report)
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.
Read More
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
